Accumulation of the nucleoside adenosine in the tumor microenvironment has been shown to inhibit the anti-tumor function of various immune cells, including cytotoxic T cells and natural killer cells, by binding to cell surface adenosine 2A receptor (A2AR). The gene discussed is ADORA2A; the disease is neoplasm.